(Cyclohexylamino) acetate | 71255-65-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Cyclohexylamino) acetate
• CAS: 71255-65-7
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: QQNPVFMSNKAMQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环己酮肟 在 吡啶 、 盐酸 、 diborane(6) 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 2.0h， 生成 (Cyclohexylamino) acetate
  参考文献：
  名称：

  Kawase,M.; Kikugawa,Y., Journal of the Chemical Society. Perkin transactions I, 1979, p. 643 - 645

  摘要：

  DOI：

文献信息

• ANTI-ANGIOGENESIS COMPOUND, INTERMEDIATE AND USE THEREOF
  申请人：GUANGZHOU HUI BO RUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20160075708A1

  公开（公告）日：2016-03-17

  Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like.

  本发明揭示了一种以化学式I表示的抗异常血管生成增殖化合物、其用途和中间体。该化合物对异常血管生成的增殖具有良好效果，其活性是通过抑制VEGFR2而产生的。该化合物可用于治疗由血管生成和蛋白激酶（如VEGFR2、FGFR2等）的异常引起的疾病，如湿性黄斑变性、炎症、恶性肿瘤等。
• A nanostarch functionalized ionic liquid containing imidazolium cation and cobalt chelate anion for the synthesis of carbamates from amines and dimethyl carbonate
  作者：Subodh Kumar、Suman L. Jain

  DOI：10.1039/c3dt52127c

  日期：——

  A new nanostarch functionalized ionic liquid containing imidazolium cation and cobalt chelate anion was synthesized and tested for the one pot synthesis of carbamates by the reaction of amines and dimethyl carbonate (DMC), affording excellent yield of the products under solvent free mild reaction conditions. The synthesized ionic liquid was easily recovered and reused several times without any loss

  合成了一种新的含咪唑鎓阳离子和钴螯合阴离子的纳米淀粉功能化离子液体，并通过胺与碳酸二甲酯（DMC）的反应进行了一次锅法合成氨基甲酸酯的试验，在无溶剂温和的反应条件下提供了优异的收率。合成的离子液体易于回收并重复使用数次，而催化效率没有任何损失。
• Isocyanate-crosslinked coating having reduced yellowing
  申请人：BASF CORPORATION

  公开号：EP0581040A1

  公开（公告）日：1994-02-02

  A coating composition is described for producing a clear or colorless coating. The composition comprises: (a) a polymer comprising at least one functional group that is reactive with isocyanate, (b) a blocked polyisocyanate, (c) a hydrazide group, either attached to the polymer (a), to the polyisocyanate (b), or part of a compound different from (a) or (b), wherein at least one of the nitrogens of the hydrazide group is not adjacent to a carbonyl.

  描述了一种用于生产透明或无色涂料的涂料组合物。该组合物包括 (a) 至少含有一个与异氰酸酯反应的官能团的聚合物、 (b) 封端多异氰酸酯、 (c) 一个酰肼基团，可连接到聚合物 (a)、多异氰酸酯 (b) 或不同于 (a) 或 (b) 的化合物的一部分，其中酰肼基团的至少一个硝基不与羰基相邻。
• 2,3-DIAMINOPROPIONIC ACID DERIVATIVE
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0725059A1

  公开（公告）日：1996-08-07

  A 2,3-diaminopropionic acid derivative represented by general formula (1) or a pharmaceutically acceptable salt thereof. This compound is useful as a platelet aggregation inhibitor, cancer metastasis inhibitor, wound remedy or bone resorption inhibitor.

  由通式（1）代表的 2,3-二氨基丙酸衍生物或其药学上可接受的盐。该化合物可用作血小板聚集抑制剂、癌症转移抑制剂、伤口治疗剂或骨吸收抑制剂。
• Elastometric articles
  申请人：Ansell Healthcare Products Inc.

  公开号：EP0922553A2

  公开（公告）日：1999-06-16

  A method of manufacturing a thin-walled polyurethane article includes dipping a shaped former into a coagulant solution and subsequently dipping the shaped former into an aqueous-phase polyurethane/plasticizer dispersion wherein the unplasticized polyurethane has a mean particle size of between about 0.5µm and 1.0µm and wherein the plasticizer causes the polyurethane particles to swell until they have a mean particle size of between about 1.5µm and 3.0µm. Articles so produced have a thickness of between 0.03mm to 1.0mm, a tensile strength of between 17 MPa and 60 Mpa and an elongation at break of greater than 650%.

  一种制造聚氨酯薄壁制品的方法包括将成型器浸入凝固剂溶液中，然后将成型器浸入水相聚氨酯/增塑剂分散液中，其中未增塑聚氨酯的平均粒径在约 0.5µm 至 1.0µm 之间，增塑剂使聚氨酯颗粒膨胀，直至其平均粒径在约 1.5µm 至 3.0µm 之间。这样生产出来的物品厚度在 0.03mm 至 1.0mm 之间，抗拉强度在 17 兆帕至 60 兆帕之间，断裂伸长率大于 650%。